Research·October 25, 2026 at 11:30 AM EDT·1 source
Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
AMGN -1.8%BMY
AMGN · last 30 trading days-1.8% since the news
News
What happened
- A Roche drug helped patients with a form of metastatic lung cancer live almost six months longer than two competing medicines.
- The competitors were medicines from Amgen and Bristol-Myers Squibb, according to the study report.
Survival advantage
almost six months
Why it matters
The result could affect competitive positioning in lung-cancer treatments and expectations for Roche’s potential blockbuster drug. It is relevant to healthcare investors and corporate-finance professionals tracking pharmaceutical pipelines.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 23Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- EarlierOct 23Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
- EarlierYesterdayAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Earlier10h#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
- First reported by Bloomberg4hRoche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
Who is involved
Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer StudyRoche Holding AGAmgenAMGNBristol-Myers SquibbBMY
Company
Sources (1)
Related
- 4h · #ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
- 10h · #ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
- Yesterday · Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Oct 23 · Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- Oct 23 · Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
- Oct 18 · Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.